[1] Cao HX,Fan JG. Fatty liver disease:a growing public health problem worldwide. J Dig Dis,2011,12:1-2.
[2] Sanyal AJ,Brunt EM,Kleiner DE,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology,2011,54:344-353.
[3] Haufe S,Engeli S,Kast P,et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology,2011,53:1504-1514.
[4] Hallsworth K,Fattakhova G,Hollingsworth KG,et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut,2011,60:1278-1283.
[5] Torres DM,Jones FJ,Shaw JC,et al. Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans:A 12-month randomized,prospective,open- label trial. Hepatology,2011,54:1631-1639.
[6] O’Shea RS,Dasarathy S,McCullough AJ. Alcoholic liver disease. AASLD Practice Guidelines. Hepatology,2010,51:307-328.
[7] Zein CO,Yerian LM,Gogate P,et al. Pentoxifylline improves nonalcoholic steatohepatitis:A randomized placebo-controlled trial. Hepatology 2011;54:1610-1619.
[8] Ratziu V,Sheikh MY,Sanyal AJ,et al. A phase 2,randomized, double-blind,placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology,2011,[Epub ahead of print]
[9] Ratziu V,de Ledinghen V,Oberti F,et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol,2011,54:1011-1019.
[10] Thoma C,Day CP,Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults:A systematic review. J Hepatol,2011,[Epub ahead of print]
[11] Mahady SE,Webster AC,Walker S,et al. The role of thiazolidinediones in non-alcoholic steatohepatitis：A systematic review and meta analysis. J Hepatol,2011,55:1383-1390. |
